Diamyd Medical AB Sustainability Reports
Diamyd Medical AB is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company is primarily engaged in developing its disease-modifying, antigen-specific immunotherapy drug candidate, Diamyd, to preserve endogenous insulin production.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 5493003NP2HNQDEKB804
FIGI: BBG004DD90Z0
8 reports from 2003 to 2025
